{
    "clinical_study": {
        "@rank": "127606", 
        "acronym": "DA-9701", 
        "arm_group": [
            {
                "arm_group_label": "Motilitone", 
                "arm_group_type": "Other", 
                "description": "take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Other", 
                "description": "take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effects of Motilitone and placebo on gastric\n      volumes, gastric emptying, small bowel transit and colon transit in female and male healthy\n      volunteers."
        }, 
        "brief_title": "Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers", 
        "condition": "Healthy Female and Male", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  no gastrointestinal symptoms\n\n          -  no organic lesion such as gastrointestinal malignancies, erosive         esophagitis,\n             reflux esophagitis, erosive gastroduodenitis, gastric or duodenal ulceration after\n             having normal upper abdominal endoscopy\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  pregnant, breast-feeding female,those of childbearing age who were not using an\n             approved method of contraception\n\n          -  history of abdominal surgery that may influence gastrointestinal motility\n\n          -  gastrointestinal hemorrhage, mechanical ileus, enterobrosis\n\n          -  irritable bowel syndrome, inflammatory bowel disease\n\n          -  severe disturbance of liver, kidney, heart,lung,blood and endocrine\n\n          -  psychoneurosis, alcoholism, drug dependence\n\n          -  medications that may alter evaluation of Motilitone including\n             antibiotics,corticosteroids, NSAID within 1 month, prokinetics, H2 blocker, PPI,\n             anticolines, erythromycin, antidepressive agents withing 2weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719575", 
            "org_study_id": "DA9701_GA_IV"
        }, 
        "intervention": [
            {
                "arm_group_label": "Motilitone", 
                "intervention_name": "Motilitone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Banpo-dong, Seocho-gu", 
                    "country": "Korea, Republic of", 
                    "state": "Seoul"
                }, 
                "name": "the Catholic university of korea college of Medicine, Seoul St.Mary's hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Two-way, Cross-over Study for Evaluating Motilitone on Gastric Motor Function in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Seul St.Mary's hospital", 
            "last_name": "Myung-Gyu Choi, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "gastric emptying time on day 4 by scintigraphic imaging", 
                "measure": "gastric fuction of Motilitone", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "fasting and postprandial gastric volume on day 7 by single photon emission computed tomography", 
                "measure": "gastric function of Motilitone", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719575"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "adverse events of Motilitone", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "small bowel transit time on day 4 by scintigraphic transit measurement", 
                "measure": "small bowel function of Motilitone", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "colon transit time on day 4 and 7 by KUB", 
                "measure": "Colon function of Motilitone", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}